1-9 of 9
lutetium
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Immune System Profiling of Waldenstrom Macroglobulinemia (WM) and Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance (IgM MGUS) Using Mass Cytometry (CyTOF)

Free
Jonas Paludo, MD, Jose Villasboas Bisneto, MD, Anne J Novak, PhD, Morie A. Gertz, MD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, Esteban Braggio, PhD, Craig B. Reeder, MD, Shahrzad Jalali, PhD, Francis K. Buadi, MB, CHB, Robert A. Kyle, MD, Stephen M. Ansell, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4138.
https://doi.org/10.1182/blood-2018-99-117568
Published: 2018
Journal Articles

LYMRIT 37-01: A Phase I/II Study of 177 lu-Lilotomab Satetraxetan (Betalutin ® ) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up

Free
Arne Kolstad, MD PhD, Ulf Madsbu, MD, Matthew Beasley, MD, Michael Bayne, MD, Tim M. Illidge, MDPhD, Noelle O'Rourke, MD, Ingemar Lagerlöf, MD, Roman Hajek, MD PhD, Wojciech Jurczak, MD PhD, Ella Willenbacher, MD, Unn Merete Fagerli, MD PhD, Aleš Obr, MD, Johan Blakkisrud, MSc, Ayca Muftuler Løndalen, MD, Lisa Rojkjaer, MD, Åse Østengen, Nils Bolstad, MD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Renate Galleberg, MD, Stine Nygaard Rudå, Harald Holte, Jr., MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2879.
https://doi.org/10.1182/blood-2018-99-110555
Published: 2018
Journal Articles

Cell Cycle Kinase Inhibitors Potentiate the Effect of 177 lu-Lilotomab Satetraxetan in Treatment of Aggressive Diffuse Large B-Cell Lymphoma Cell Lines

Free
Gro Elise Rødland, PhD, Katrine Melhus, Jostein Dahle, PhD, Randi Syljuåsen, PhD, Sebastian Patzke, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1371.
https://doi.org/10.1182/blood-2018-99-110200
Published: 2018
Journal Articles

177 Lu-Lilotomab Satetraxetan, a Novel CD37-Targeted Antibody-Radionuclide Conjugate in Relapsed Non-Hodgkin's Lymphoma (NHL): Updated Results of an Ongoing Phase I/II Study (LYMRIT 37-01)

Free
Arne Kolstad, MD PhD, Ulf Madsbu, MD, Matthew Beasley, MD, Michael Bayne, MD, Tim M. Illidge, MDPhD, Noelle O'Rourke, MD, Ingemar Lagerlöf, MD, Roman Hájek, MD, Wojciech Jurczak, PhDMD, Ella Willenbacher, MD, Johan Blakkisrud, MSc, Ayca Muftuler Løndalen, MD, Lisa Rojkjaer, MD, Laurie Baylor Curtis, MSc, Marianne Bloma, MSc, Simon Turner, PhD, Nils Bolstad, MD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Unn Merete Fagerli, MD, Renate Galleberg, MD, Stine Nygaard Rudå, Harald Holte
Journal: Blood
Blood (2017) 130 (Supplement 1): 2769.
https://doi.org/10.1182/blood.V130.Suppl_1.2769.2769
Published: 2017
Journal Articles

177 lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens

Free
Arne Kolstad, MD PhD, Ulf Madsbu, Matthew Beasley, Michael Bayne, Tim Illidge, Noelle O'Rourke, Caroline Stokke, Tore Bach-Gansmo, Ayca Muftuler Løndalen, Jon Erik Holtedahl, Mona Elisabeth Revheim, Øyvind Bruland, Jostein Dahle, Laurie Baylor Curtis, Åse Østengen, Simon Turner, Nils Bolstad, Roy Hartvig Larsen, Signe Spetalen, Martin Erlanson, Stine Nygaard Rudå, Harald Holte
Journal: Blood
Blood (2016) 128 (22): 1780.
https://doi.org/10.1182/blood.V128.22.1780.1780
Published: 2016
Journal Articles

Combination of 177 lutetium-Satetraxetan-Lilotomab and Rituximab Results in Improved Therapeutic Effect in Preclinical Models of Non-Hodgkin Lymphoma

Free
Ada H.V. Repetto-Llamazares, PhD, Roy Hartvig Larsen, PhD, Adam O'Shea, Jostein Dahle
Journal: Blood
Blood (2016) 128 (22): 4189.
https://doi.org/10.1182/blood.V128.22.4189.4189
Published: 2016
Journal Articles

Efficacy and Safety Results of a Phase 1 Study of 177 lu-DOTA-HH1 (Betalutin ® ) with and without HH1 Pre-Dosing for Patients with Relapsed CD37+ Non-Hodgkin B Cell Lymphoma (NHL)

Free
Arne Kolstad, MD PhD, Ulf Madsbu, MD, Bjørg Bolstad, MSc, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Jostein Dahle, PhD, Nils Bolstad, MD, Roy Hartvig Larsen, PhD, Signe Spetalen, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, Jr., MD PhD
Journal: Blood
Blood (2015) 126 (23): 5118.
https://doi.org/10.1182/blood.V126.23.5118.5118
Published: 2015
Journal Articles

A Phase I Study of 177 lu-DOTA-HH1 (Betalutin) Radioimmunotherapy for Patients with Relapsed CD37+ Non-Hodgkin's B Cell Lymphoma

Free
Arne Kolstad, MD PhD, Ulf Madsbu, MD, Jostein Dahle, PhD, Caroline Stokke, PhD, Tore Bach-Gansmo, MD PhD, Ayca Muftuler Løndalen, MD, Jon Erik Holtedahl, MSc, Mona Elisabeth Revheim, MD PhD, Øyvind Bruland, MD PhD, Bjørg Bolstad, MSc, Nils Bolstad, MD, Anne Tierens, MD PhD, Roy Hartvig Larsen, PhD, Jan Alan Alfheim, MSC, MBA, Jan Delabie, MD PhD, Spetalen Signe, MD, Martin Erlanson, MD PhD, Stine Nygaard Rudå, Harald Holte, MD PhD
Journal: Blood
Blood (2014) 124 (21): 3094.
https://doi.org/10.1182/blood.V124.21.3094.3094
Published: 2014
Journal Articles

Radioimmunotherapy (RIT) with 177 Lutetium-DOTA-Rituximab ( 177 LU-D- R): A Phase I/II - Study in 30 Patients with Relapsing Follicular, Mantle Cell and Other Indolent B-Cell Lymphomas

Free
Andreas Lohri, MD, Flavio Forrer, MD, PhD, Benedetta Campana, Christoph Mamot, MD, Ralph Winterhalder, MD, Richard Herrmann, MD, Helmuth R Maecke, PhD, Jan Müller-Brand, MD
Journal: Blood
Blood (2008) 112 (11): 3055.
https://doi.org/10.1182/blood.V112.11.3055.3055
Published: 2008